This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.

Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

While Bio-Techne stock has underperformed the broader market over the past year, analysts remain moderately bullish about its ...

On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.

Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Which news ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

BIO boosts ddPCR growth with the Stilla acquisition, QX700 launch and expanded assays for molecular testing. Bio-Rad's clinical diagnostics sees strong demand, led by IH-500 NEXT and growth in ...

Bio-Path (NASDAQ:BPTH) stock is rising higher on Friday alongside data from the oncology-focused company’s Phase 2 clinical trial of prexigebersen. Prexigebersen is Bio-Path product candidate for the ...

On Thursday, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year ...

Tevogen Bio (NASDAQ:TVGN) stock is seeing a surprising amount of movement on Thursday after the clinical-stage biotechnology company announced a new head of Investor Relations and Corporate ...